Feature Type | Standardized | Nominal ANOVA | ||||
---|---|---|---|---|---|---|
mRNA | Tamoxifen | CTRPv2 | pan-cancer | AAC | 0.052 | 0.2 |
mRNA | Crizotinib | gCSI | pan-cancer | AAC | -0.078 | 0.2 |
mRNA | COL-3 | CTRPv2 | pan-cancer | AAC | -0.052 | 0.2 |
mRNA | IPR-456 | CTRPv2 | pan-cancer | AAC | -0.052 | 0.2 |
mRNA | LBW242 | CCLE | pan-cancer | AAC | 0.062 | 0.2 |
mRNA | CIL41 | CTRPv2 | pan-cancer | AAC | 0.068 | 0.2 |
mRNA | tanespimycin:gemcitabine (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.043 | 0.2 |
mRNA | BRD-K33199242 | CTRPv2 | pan-cancer | AAC | 0.051 | 0.2 |
mRNA | thalidomide | CTRPv2 | pan-cancer | AAC | 0.073 | 0.2 |
mRNA | CHIR-99021 | CTRPv2 | pan-cancer | AAC | 0.045 | 0.2 |